Read our Recent Headlines

ASH Update: TRIL

Trillium Therapeutics presented interim data from its ongoing Phase 1 trial of the SIRPaFc TTI-621 at ASH this past weekend. These highly anticipated results gave a deeper look into the.

December 5 Biotech Update

ASH has more or less come and gone. This is usually a highly anticipated conference that has some game changing data. While this was once again highly anticipated, I have.

December 2 Biotech Update

ASH starts soon and the sector needs some more positive news as it is really starting to lag. Outside of the initial election pop it has been pretty bad in.

November 30 Biotech Update

We are in a lull before a flood of data arrives at the end of this week and then into ASH next week. There is not a lot of new.

November 29 Biotech Update

It seems like the election move is taking a time out and some consolidation is happening. That is not surprising given the move and (at least for the sector) the.

November 28 Biotech Update

I vaguely (not really vaguely) recall noting last Tuesday that we were likely done with news unless some company wanted to sneak bad news in right before the holiday. I.

November 22 Biotech Update

More of the same in terms of slow news and likely decreasing volumes into the weekend. We do have a couple pieces of fundamental news to talk about but nothing.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!